# Labcorp Holdings Inc. (LH) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Biotechnology. Price $326.89, market value $26.5 billion.

## Valuation
- **P/E (trailing): 27.0×** (5-yr avg 24.0×, 3-yr avg 31.9×). Labcorp Holdings Inc. trades at 27.0× trailing earnings, close to its own five-year average of 24.0×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 16.5×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.90**. A PEG of 0.90 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 1.8×**. Each dollar of revenue is priced at 1.8×.
- **Price / book: 3.1×**. The shares trade at 3.1× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 14.4×**. Enterprise value is 14.4× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 4.4%** (5-yr avg 7.1%). Free cash flow equals 4.4% of the market value, below its five-year average of 7.1%, so the shares are pricier on cash than usual.
- **Earnings yield: 3.7%**. The inverse of the P/E: 3.7% of the price is earned each year.

## Profitability
- **Gross margin: 28.9%**. Labcorp Holdings Inc. keeps 28.9% of revenue after the direct cost of what it sells.
- **Operating margin: 10.4%**. 10.4% of revenue is left after running the business.
- **Net margin: 6.3%**. 6.3% of each dollar of sales reaches the bottom line.
- **Return on equity: 10.2%**. 10.2% on shareholders' equity is solid.
- **Return on invested capital: 8.6%**. Return on all capital, debt included, is 8.6%.
- **Return on assets: 5.4%**. Each dollar of assets produces 5.4% of profit.

## Growth
- **Revenue growth (1 yr): 7.2%** (3-yr 5.6%/yr, 5-yr -0.0%/yr). Revenue grew 7.2% over the last year, against -0.0% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 18.3%** (3-yr -9.2%/yr, 5-yr -8.0%/yr). Earnings per share rose 18.3%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): -7.6%/yr**. Free cash flow has compounded at -7.6% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.65**. Debt is 0.65 times equity, moderate leverage.
- **Net debt / EBITDA: 2.3×**. It would take 2.3 years of operating earnings to repay net borrowings, within the comfortable range.
- **Altman Z-score: 3.29**. A Z-score of 3.29 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 8/9**. 8 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend yield: 0.88%** ($2.88 per share, trailing). Labcorp Holdings Inc. yields 0.88%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 27%** (21% of free cash flow). 27% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 4**. 4 straight years of increases.

## Analyst view
- **Analyst consensus: buy** (16 analysts). 16 analysts cover Labcorp Holdings Inc.; the consensus is buy, with an average price target of $341.50 (+4% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 19.7%** (YTD 31.0%, 3-mo 23.3%). The shares are up 19.7% over twelve months including dividends.
- **From 52-week high: -4.4%** (33.7% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 55**. An RSI of 55 is neutral.
- **Beta (1 yr): 0.28** (volatility 23%). Beta of 0.28 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=LH · Page: https://foliofundamentals.com/stocks/lh

Not investment advice.